Document is current
Any future updates will be listed below
-
Authors
Yang, Kaiting https://orcid.org/0000-0001-9328-5655
Han, Wenbo
Jiang, Xiaomin
Piffko, Andras https://orcid.org/0000-0001-5300-6594
Bugno, Jason
Han, Chuanhui
Li, Sirui https://orcid.org/0000-0002-1645-6868
Liang, Hua
Xu, Ziwan
Zheng, Wenxin
Wang, Liangliang https://orcid.org/0000-0001-8340-5190
Wang, Jiaai
Huang, Xiaona
Ting, Jenny P. Y.
Fu, Yang-Xin
Lin, Wenbin https://orcid.org/0000-0001-7035-7759
Weichselbaum, Ralph R. https://orcid.org/0000-0002-5643-8939
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft
Clinical Therapeutics Training Grant
Foundation for the National Institutes of Health (R01AI141333, R35CA232109, R01CA223184, R01CA216436, R01CA262508)
Ludwig Institute for Cancer Research
- License Information
-
More Information
Article History
Received: 3 November 2021
Accepted: 5 September 2022
First Online: 27 October 2022
Competing interests
: R.R.W. has stock and other ownership interests with Boost Therapeutics, Immvira, Reflexion Pharmaceuticals, Coordination Pharmaceuticals, Magi Therapeutics and Oncosenescence. R.R.W. has served in a consulting or advisory role for Aettis, AstraZeneca, Coordination Pharmaceuticals, Genus, Merck Serono, Nano proteagen, NKMax America and Shuttle Pharmaceuticals. R.R.W. has a patent pending entitled ’Methods and kits for diagnosis and triage of patients with colorectal liver metastases’ (US Patent application no. PCT/US2019/028071). R.R.W. has received research grant funding from Varian and Regeneron. R.R.W. has received compensation, including travel, accommodations or expense reimbursement, from AstraZeneca, Boehringer Ingelheim and Merck Serono. W.L. is the founder and chairman of Coordination Pharmaceuticals, which licensed the NCP technology from the University of Chicago. The other authors have no competing interests.
